A new study on elamipretide was published on October 5, 2026, in Frontiers in Pharmacology. The publication is titled "Mitochondria-targeted peptide elamipretide alleviates cisplatin-induced ovarian failure by activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway." This publication is indexed under PubMed ID 42898512. The title describes research into elamipretide in the context of cisplatin-induced ovarian failure and the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway. No findings, outcomes, or efficacy data beyond the title are provided here. Readers interested in the full scope of the study are encouraged to consult the original publication directly through the listed source. Elamipretide is currently classified as an approved compound. For broader context on elamipretide, including its regulatory status and general background, readers can refer to the compound overview.
Elamipretide Study Published in Frontiers in Pharmacology
See the full elamipretide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42898512/